Table 2.
Pharmacokinetic parameters (mean ± SD) calculated for sustained release cephalexin following an intramuscular (IM) and subcutaneous (SC) 8 mg/kg injection to 6 llamas.
| Parameter | Route of administration | |
|---|---|---|
| IM | SC | |
| C max (μg/mL) | 11.7 ± 1.6a | 8.2 ± 2.4a |
| T max (h) | 1.75 ± 0.3a | 3.33 ± 0.5b |
| λ (h−1) | 0.46 ± 0.13a | 0.31 ± 0.10a |
| t 1/2λ (h) | 1.60 ± 0.4a | 2.65 ± 1.7a |
| AUC0–last (μg·h/mL) | 59.5 ± 6.7a | 57.7 ± 12.3a |
| AUC0–inf (μg·h/mL) | 60.2 ± 6.7a | 57.9 ± 12.4a |
| MRTlast (h) | 3.5 ± 0.6a | 5.1 ± 1.2b |
| MRTinf (h) | 3.7 ± 0.7a | 6.1 ± 2.5a |
| F (%) | 87 ± 10a | 84 ± 18a |
a.bValues within a row with different superscripts indicate significant differences (p < 0.05).
C max: peak serum concentration; T max: time to reach peak serum concentration; λ: apparent terminal rate constant; t 1/2λ: terminal half-life; AUC0–last: area under the serum concentration-time curve from time zero to last point; AUC0–∞: area under the serum concentration-time curve from time zero to infinity; MRT: mean residence time; F: absolute bioavailability.